The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision
The company has secured 506 marketing approvals for its oncology products across 76 countries.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
The product basket increased to 1800 medicines and 285 Surgical Equipment
More than 9600 Pradhan Mantri Bhartiya Janaushadhi Kendras have been set up covering all districts of the country to promote generic medicines at affordable prices
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Take proper precautions and seek timely treatment!
Marks the World Head & Neck Cancer Day at the OCTF Conference
Uses a simple mechanical approach for removing intrauterine tissues
Subscribe To Our Newsletter & Stay Updated
